Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and Amicus Therapeutics have started patient dosing in a randomized, open-label, 18-month second of two Phase III (Study 012) study to compare the efficacy and safety of Amigal (migalastat HCl) and enzyme replacement therapy (ERT) to treat Fabry disease.
Subscribe to our email newsletter
The companies expect to recruit around 50 male and female patients suffering from Fabry disease and who are presently receiving ERT treatment, and who have a genetic mutation that may be addressable with migalastat HCI.
The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).
Amicus chairman and CEO John Crowley said this is an important step in their clinical development plan and builds on the latest encouraging safety and renal function data from our ongoing Phase II extension study.